Industry landscapes
The companies, capital and talent shaping healthtech in Switzerland. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
73 of 1,182 tracked companies have open roles.
228 of 1,182 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 463 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 25.3% of disclosed capital, while 80.7% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $241.48M | 53 | 17 |
| 2017 | $124.15M | 60 | 21 |
| 2018 | $176.14M | 75 | 38 |
| 2019 | $202.3M | 83 | 47 |
| 2020 | $334.64M | 82 | 46 |
| 2021 | $487.24M | 54 | 51 |
| 2022 | $426.55M | 44 | 47 |
| 2023 | $421.66M | 40 | 32 |
| 2024 | $443.67M | 35 | 34 |
| 2025 | $860.07M | 12 | 32 |
Share of all disclosed company funding.
560 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Protocol Labs and IAG Capital Partners and others.
Backed by Redstone and Concept Ventures and others.
Backed by .
Backed by Apollo Global Management.
Backed by WI Harper Group and Privilege Ventures and others.
Backed by Revival Healthcare Capital.
Backed by Revival Healthcare Capital.
Participating investors were not recorded in this snapshot.
Backed by UBS and Endeavour Vision and others.
Backed by aMoon and Hitachi Brand and others.
Backed by Concord Health Partners and AlbaCore Capital Group and others.
Backed by Woodford Investment Management and Arthurian Life Sciences and others.
Backed by Hinduja Group.
Backed by Revival Healthcare Capital and 415 CAPITAL.
Backed by Generation Investment Management and Idinvest Partners and others.
No reviewed exact national-ID connector has yet been qualified for Switzerland; this is a checked implementation boundary, not evidence that filings are absent.
How the Switzerland companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
13 of the 1,182 companies on this page carry a measured traffic record (1.1%); these are the largest of those, by monthly visits. The median among them is 349,398 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Clearblueclearblue.com | 1,112,993 | 65 | 92.2% |
| Phonakphonak.com | 1,030,142 | 52 | 86.5% |
| OneDoconedoc.ch | 754,719 | 48 | 61.9% |
| Redcare Apothekeredcare-apotheke.ch | 442,238 | 45 | 68.2% |
| MediDatamedidata.ch | 418,839 | 27 | 76.6% |
| LogicRdvlogicrdv.fr | 365,161 | 37 | 73% |
| Coop Vitalitycoopvitality.ch | 349,398 | 47 | 66.3% |
| SWICAswica.ch | 346,975 | 45 | 54.8% |
| Unaidsunaids.org | 187,776 | 56 | 47.7% |
| Ascensiaascensia.com | 102,658 | 33 | 93.1% |
Visits and authority are third-party web estimates, not company-reported figures.
131 of these companies (11.1%) publish at least one Android app — 279 apps in all, carrying 13.8M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| myPhonakPhonak | 4.2M | 4.5 | Medical |
| Ornament: Your Health CoachOrnament | 1.3M | 1.9 | Health & Fitness |
| Medela Family - Breast FeedingMedela | 906.1K | 4.3 | Medical |
| CONTOUR DIABETES app (US)Ascensia | 443.5K | 3.3 | Medical |
| Lucidity ― Lucid Dream JournalLucidity | 412.4K | 4.4 | Health & Fitness |
| MedgateMedgate | 395.9K | — | Medical |
| Blood Pressure Diary by MedMMedM | 360.3K | 4.4 | Medical |
| Period TrackerClearblue | 335.3K | 4.5 | Health & Fitness |
| TOM Medication & Pill ReminderTOM | 311K | 3.6 | Medical |
| Blood Sugar Diary for DiabetesMedM | 274.9K | 4.5 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Wearable Technology | 19 | 5.7M | myPhonak 4.2M | |
| Consumer Electronics E-Commerce | 11 | 5.4M | Medela Family - Breast Feeding 906.1K | |
| Audio Tech | 5 | 4.3M | myRogerMic 63.3K | |
| Disease Self Management | 65 | 3.6M | Ornament: Your Health Coach 1.3M | |
| Diabetes | 64 | 2.5M | CONTOUR DIABETES app (US) 443.5K | |
| Healthcare It | 109 | 2.2M | Medgate 395.9K | |
| Women Health | 6 | 1.1M | Ava Fertility 112.9K | |
| Healthcare Booking Platforms | 27 | 1.1M | Well. Your health – digitally 233.3K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 140 of 279 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
38 companies hiring · $3.96B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Dental start-up vVardis’ most recent investment means it is now valued at more than USD 1 billion.
Pregnolia (2016, ZH) developed a medical device for the improvement of pregnancy care, which allows health care providers to measure the stiffness of the cervix for a more complete characterization of cervical status. The company has been selected as recipient of blended finance from EIC.
Complete Genomics, a U.S.-based innovator in genomic sequencing technology, today confirmed that it has entered into a definitive agreement, subject to customary closing conditions and approval by MGI shareholders, under which it will be acquired by Swiss Rockets AG, a Switzerland-based life sciences group.
New Delhi: Alkem Laboratories Limited announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has made a binding offer dated February 13, 2026, to acquire between 51% and 55% of the total issued equity share capital of Switzerland-based Occlutech Holding AG from certain existing shareholders.
Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors.
Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Facility") entered into on 17 March 2025 between the Company and GEM Global Yield LLC SCS ("GEM"). Under the terms of the Facility, GEM has agreed, subject to certain conditions, to commit an amount of up to EUR 20 million in cash...
SamanTree Medical a Liège-based startup innovating in surgical imaging, has secured €20 million in financing from the European Investment Bank (EIB) to develop an advanced confocal microscopy scanner for rapid imaging of tissue microstructures during surgery.
Claret Capital Partners — a growth debt fund manager with a focus in technology, life sciences and climate tech companies across Europe — completed a strategic investment in Swiss medtech company SIS Medical.
Liom, the Swiss glucose monitoring startup, announced a €13.9 million extension to its Series A funding round, bringing its Series A total to €40.8 million.
Sonova has acquired the remaining majority stake in SilentCloud to advance its digital health and hearing care strategy.
Top 10 categories among 315 recorded events in the 24-month window.
2 companies with recorded IPO activity
Follow-on Offering · Nasdaq3 reports
IPO activity1 reports
18 tracked people moves
Appointment Head of its Beauty Business Unit
Appointment President and CEO
Appointment Chief Executive Officer
Appointment Executive President
Appointment Chief Business Officer
Resignation Previously Chief Executive Officer
Appointment Chairman of the Board of Directors
Appointment Deputy of the Board of Directors
Products, platforms and features in the recorded window
Product
13 recorded customer wins
Customer: magnavaleCold storage
Customer: satair
Customer: senseonicsDiabetes Technology
Customer: Asia Pacific Life Sciences Group Ltd.biopharma
Customer: astrazenecaHealthcare
Customer: costco
2 companies with reported reductions
52 rolescash runway extension
Scale not stated rolescost reduction
2 recorded events
Reported company results in the recorded window.
Median across 38 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Swiss Rockets→complete genomics | Completed | 2026-03-02 | Not stated in snapshot |
| Alkem Medtech→Occlutech ↗ | Announced | 2026-02-16 | Not stated in snapshot |
| Sonova→SilentCloud | Announced | 2025-12-22 | Not stated in snapshot |
| Medartis→Keri Medical ↗ | Announced | 2025-09-10 | Not stated in snapshot |
| Orlando Capital V→PENTAPHARM ↗ | Completed | 2025-08-01 | Not stated in snapshot |
| NeuroX→MindMaze ↗ | Completed | 2025-07-29 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
214 postings in the preceding 12 months. The full 833-posting snapshot covers 39 employers.
1 tracked postings mention remote work.
354 postings specify a level.
Top skills across 833 tracked postings in the available jobs snapshot.
| Company | Open roles |
|---|---|
| Sonova ↗ | 11 |
| Aeon ↗ | 8 |
| Straumann Group ↗ | 8 |
| WePractice ↗ | 8 |
| Sentec ↗ | 8 |
| Hamilton Medical ↗ | 7 |
| Swisslog ↗ | 7 |
| Sophia Genetics ↗ | 7 |
| Company | Employees |
|---|---|
| Sonova ↗ | 17,608 |
| Tecan ↗ | 2,318 |
| Metall Zug ↗ | 2,312 |
| Medmix ↗ | 2,245 |
| SWICA ↗ | 1,208 |
| Medartis ↗ | 858 |
| Phonak ↗ | 772 |
| Inpeco ↗ | 544 |
680 founders and chief executives across 467 companies.
Cequr, ex-Stryker, ex-Microchips, Kellogg School of Management, Chicago, 2012
Ex-Zimmer Biomet, Stryker. Miami University BA 1995, Cleveland State University JD 1998
Co-CEO-MindMaze · Ex-Bayer Pharmaceuticals, Voluntis, Sanofi · Sciences Po 1996, Paris Dauphine University - PSL 1998, HEC Paris 1998
Co-Founder Flamboyant, Founder HIM, ex- CFO ARTEMIS Augenkliniken und med. Versorgungszentren, CFO AMEOS Group. University of Mannheim 2000…
Co-Founder & CEO SOPHiA GENETICS. University of Bordeaux 2002, University of Geneva PhD 2007
Xeltis, ex-The Medicines, ex-Profibrix, Maastricht University, 2004
Ex-Nestle, AB2Bio. University of Wurzburg PhD
Ex-B. Braun Group. University of Cambridge 1993
Ex-GC Aesthetics, Circassia, Jefferies, Ferghana Partner, Deutsche Bank.
ex-Medtronic, Vexim, Stryker. Joseph Fourier University 2000.
Ex-Swiss Center for Electronics and Microtechnology. EPFL MSc 2001, PhD 2005
Ex-CEO Syntach AG, Novo Nordisk, Viggo AB. Lund University BSc 1983, IMD MBA 1988
67 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
392,469 articles in the measured 12-month window.
Healthtech coverage across Switzerland · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 32,965 |
| 2021Q3 | 33,392 |
| 2021Q4 | 29,843 |
| 2022Q1 | 34,691 |
| 2022Q2 | 34,204 |
| 2022Q3 | 33,562 |
| 2022Q4 | 44,178 |
| 2023Q1 | 45,741 |
| 2023Q2 | 43,597 |
| 2023Q3 | 37,694 |
| 2023Q4 | 35,353 |
| 2024Q1 | 49,489 |
| 2024Q2 | 57,033 |
| 2024Q3 | 53,339 |
| 2024Q4 | 52,800 |
| 2025Q1 | 80,672 |
| 2025Q2 | 47,012 |
| 2025Q3 | 291,463 |
| 2025Q4 | 24,033 |
| 2026Q1 | 37,987 |
Article volume measures coverage, not market sales.
425 recorded company events across 55 companies; percentages use that event total.
Healthtech coverage across Switzerland · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Switzerland
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,193 | 1,858 | 126% |
| tariff negotiations | 2,208 | 703 | 214% |
| free trade deals | 1,237 | 373 | 232% |
| trade dispute mechanisms | 1,124 | 254 | 343% |
| bilateral trade | 1,021 | 240 | 325% |
| multilateral diplomacy | 543 | 244 | 123% |
| diplomatic strategies | 541 | 321 | 69% |
| preferential tariff | 517 | 196 | 164% |
| trade barrier reduction | 466 | 145 | 221% |
| women\'s champions league | 463 | 170 | 172% |
| europa league | 160 | 902 | -82% |
| quarterfinals | 237 | 677 | -65% |
| final match | 145 | 639 | -77% |
| final match recaps | 258 | 548 | -53% |
| multilateral accords | 166 | 280 | -41% |
Healthtech coverage across Switzerland
territories, disputed islands, countries
11.2% critical · 8.5% positivecurrency intervention policies, inflation reports fx, trade deficits fx
38.5% critical · 43.9% positivegdp growth forex, inflation reports fx, currency intervention policies
31.8% critical · 47.7% positiveHealthtech coverage across Switzerland. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 37.7% |
| Problem-identifying | 29.0% | 9.8% |
| Descriptive | 18.8% | 17.2% |
| Breakthrough | 12.7% | 26.2% |
| Cautionary | 6.4% | 4.5% |
| Comparative | 2.5% | 3.8% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
39.5% across the displayed hubs
13 companies hiring · $710.6M disclosed funding
Explore companies in Zurich ↗
14.4% across the displayed hubs
7 companies hiring · $847.9M disclosed funding
Explore companies in Lausanne ↗
12.2% across the displayed hubs
6 companies hiring · $59.5M disclosed funding
Explore companies in Basel ↗
11.0% across the displayed hubs
6 companies hiring · $172.9M disclosed funding
Explore companies in Geneva ↗
9.3% across the displayed hubs
5 companies hiring · $79.5M disclosed funding
Explore companies in Bern ↗
7.4% across the displayed hubs
5 companies hiring · $369.1M disclosed funding
Explore companies in Zug ↗
3.2% across the displayed hubs
1 companies hiring · $68.6M disclosed funding
Explore companies in Schlieren ↗
3.1% across the displayed hubs
1 companies hiring · $51.3M disclosed funding
Explore companies in Baar ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗